Researchers sought to determine whether fixed-duration treatment with venetoclax + obinutuzumab/ibrutinib would have similar efficacy to continuous ibrutinib therapy in CLL.

Richter transformation with CNS involvement in CLL patients results in poor prognosis and limited survival, with a median overall survival of 13 months. Treatment strategies for RT-CNS are often ...

June 11, 2009 (Berlin, Germany) — The novel CD20 monoclonal antibody ofatumumab (Arzerra) has demonstrated superior response rates in 2 challenging groups of chronic lymphocytic leukemia (CLL) ...

The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.

Continuous and fixed-duration ibrutinib-based regimens deliver survival outcomes for CLL patients comparable to an age-matched European population. The study supports current CLL treatment ...

INDIANAPOLIS, April 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-322 trial of Jaypirca (pirtobrutinib), a non-covalent ...

SAN DIEGO -- The scientific program of the American Society of Hematology (ASH) annual meeting included thousands of posters presented over a period of 3 days. A selected few on chronic lymphocytic ...

Consistent with the overall study cohort, recipients of immunoglobulin replacement therapy who had been hospitalized for a serious infection in the past month showed a higher 30-day mortality rate per ...

Please provide your email address to receive an email when new articles are posted on . Serious infections in patients with chronic lymphocytic leukemia have doubled despite increased use of ...

(ORLANDO, Dec. 6, 2025) According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination ...

Leukemia refers to cancer of the blood cells and bone marrow. There are four main types, each associated with a different outlook and life expectancy. Healthcare professionals classify the different ...

Many patients with chronic lymphocytic leukemia (CLL) are treated with two- or three-drug regimens, but for some patients just one drug may be enough. Particularly for older patients or those who are ...